Kidney disease

Standard treatments, such as renin-angiotensin-aldosterone system inhibitors, should be used as first line treatment please see local guidelines.

1 tablet daily.

Chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults

Refer to local EdRen guidelines

Prescribing Notes:

Local prescribing advice on how to start an SGLT-2 Inhibitor in diabetic and non-diabetic chronic kidney disease on EdRen.
Refer to EdRen for local prescribing advice on finerenone in diabetic chronic kidney disease.
Sick day rules are applicable to SGLT-2 inhibitors and finerenone.
Included on the formulary with criteria added in addition to SMC advice. Refer to EdRen website for local criteria - upper eGFR limit removed as not reported by labs, PCR measurement used locally rather than ACR.

06/02/2025

Addition of empagliflozin (SMC2642) in line with local guidance, ERFC Dec 24

09/04/2024

Addition of Finerenone SMC 2486, ERFC Dec 23.

20/04/2023

East Region Formulary content agreed.

View all

Dose as per specialist.

Tolvaptan is a vasopressin V2 receptor antagonist that slows the loss of kidney function in patients with autosomal dominant polycystic kidney disease, partly by reducing the rate of kidney cyst growth. These benefits are greatest in those patients at high risk of kidney decline as identified by strict clinical and imaging criteria. Tolvaptan is prescribed in secondary care but requires regular monitoring of liver function tests. Sick day rules are applicable and there are important interactions with antimicrobials that should be checked prior to new prescriptions.

20/04/2023

East Region Formulary content agreed.